What does this research mean for the field?

The combination of high-dose continuous infusion of 5-fluorouracil with leucovorin and recombinant interferon-alpha-2b results in a 25% partial response rate in patients with advanced colorectal cancer. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The research aimed to evaluate the efficacy and toxicity of a high-dose 5-FU regimen combined with leucovorin and interferon-alpha in patients with advanced colorectal cancer.

March 1, 2026Journal of Marine Fisheries

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study

View Full Paper

Ask AI

Bookmark

Authors

CPC. J. PuntUniversity Vascular Associates JBJ. T. Burghouts JCJ. J. Croles

Discussion

Member takes

Implication

Phase II study shows partial responses in advanced colorectal cancer with combined therapy, suggesting new treatment possibilities.

Key Points

The research aimed to evaluate the efficacy and toxicity of a high-dose 5-FU regimen combined with leucovorin and interferon-alpha in patients with advanced colorectal cancer.
Forty-five patients received high-dose 5-FU via continuous intravenous infusion for two days.
Leucovorin was administered orally every 6 hours during the infusion period.
Recombinant interferon-alpha-2b was given subcutaneously on specific days in the treatment cycle.
Treatment cycles were repeated weekly for four weeks, then every two weeks.
11 out of 44 evaluable patients achieved a partial response (25%) with a median duration of 11 months.
Median survival time for all patients was reported at 11 months.
47% of patients experienced Grade 3 or 4 toxicities, leading to treatment discontinuation in 4% and dose reductions in 24%.
The combination showed similar efficacy to prior treatments but resulted in less toxicity compared to bolus 5-FU.

Cite This Study

Punt et al. (1993) studied this question.

synapsesocial.com/papers/69a3d6eaec16d51705d2d9b4 https://doi.org/10.1002/1097-0142(19931001)72:7

View Full Paper

Ask AI

Bookmark

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study

Discussion

Member takes

Implication

Key Points

Cite This Study

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider